title: Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment.
abstract: Treatment advances for multiple myeloma (MM) that have prolonged survival emphasise the importance of measuring patients' health-related quality of life (HRQoL) in clinical studies. HRQoL/functioning and symptoms of patients with relapsed/refractory MM (RRMM) receiving second- or third-line lenalidomide or bortezomib treatment were measured in a prospective European multicentre, observational study at different time points. At baseline, patients in the lenalidomide cohort were frailer than in the bortezomib cohort with more rapid disease progression at study entry (more patients with Eastern Cooperative Oncology Group performance status >2, shorter time from diagnosis, more chronic heart failure, higher serum creatinine levels, more patients with dialysis required). About 40% of the patients receiving lenalidomide discontinued the study in <6 months while 55% in the bortezomib cohort discontinued. No substantial HRQoL deterioration was observed for the first 6 months in patients with RRMM receiving one or the other treatment. For patients still on treatment at study completion (month 6), only the European Organization for Research and Treatment of Cancer Quality-of-Life Core domains of Diarrhoea and Global Health Status/QoL had worsened in the lenalidomide and bortezomib cohorts, respectively. A clinically meaningful deterioration in HRQoL was more often observed for patients who discontinued the study prior to 6 months in the bortezomib cohort than in the lenalidomide cohort.
authors.affiliation: Hopital de La Milétrie - CHU and CIC Inserm 1402, Poitiers, France.
authors.forename: X
authors.initials: X
authors.lastname: Leleu
authors.affiliation: Royal Free and Northwick Park Hospitals, London, UK.
authors.forename: C
authors.initials: C
authors.lastname: Kyriakou
authors.affiliation: Iridium Kankernetwerk, Sint-Niklaas, Belgium.
authors.forename: I
authors.initials: I
authors.lastname: Vande Broek
authors.affiliation: Beaumont Hospital, Dublin, Ireland.
authors.forename: P
authors.initials: P
authors.lastname: Murphy
authors.affiliation: Celgene International Sarl, Boudry, Switzerland.
authors.forename: P
authors.initials: P
authors.lastname: Bacon
authors.affiliation: Celgene GmbH, Munich, Germany.
authors.forename: P
authors.initials: P
authors.lastname: Lewis
authors.affiliation: Patient-Centered Outcomes, Mapi, Lyon, France.
authors.forename: H
authors.initials: H
authors.lastname: Gilet
authors.affiliation: Patient-Centered Outcomes, Mapi, Lyon, France.
authors.forename: B
authors.initials: B
authors.lastname: Arnould
authors.affiliation: Division of Hematology, Department of Cellular Biotechnology and Hematology, Sapienza University of Rome, Rome, Italy.
authors.forename: M T
authors.initials: MT
authors.lastname: Petrucci
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D000069286:Bortezomib / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015897:Comorbidity; D019008:Drug Resistance, Neoplasm; D005060:Europe; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D011788:Quality of Life; D012008:Recurrence; D019233:Retreatment; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide